| Code | CSB-RA023984MB4HU |
| Size | |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to AGEN-2373, targeting TNFRSF9 (Tumor Necrosis Factor Receptor Superfamily Member 9), also known as 4-1BB or CD137. TNFRSF9 is an inducible costimulatory receptor expressed primarily on activated T cells and natural killer cells, playing a critical role in enhancing T cell proliferation, survival, and cytotoxic function. Upon binding with its ligand 4-1BBL, TNFRSF9 delivers potent costimulatory signals that augment anti-tumor immune responses. This pathway has emerged as a promising target in cancer immunotherapy, particularly for enhancing cytotoxic T lymphocyte activity against solid tumors and hematological malignancies.
AGEN-2373 represents a next-generation agonistic antibody designed to selectively activate TNFRSF9 signaling in the tumor microenvironment while minimizing systemic toxicity. This biosimilar antibody serves as a valuable research tool for investigating TNFRSF9-mediated immune modulation, studying T cell activation mechanisms, exploring combination immunotherapy strategies, and evaluating immune checkpoint pathways in oncology research and immunological studies.
There are currently no reviews for this product.